Nearly 1 in 10 U.S. adults used a GLP-1 drug in the past year, CDC survey finds
A new federal survey shows 44% of people taking semaglutide or tirzepatide altered their regimen — most often by skipping doses — citing cost and supply problems, while a fifth of users took a compounded version never reviewed by the FDA for safety.

Nearly one in 10 American adults took a GLP-1 medication such as semaglutide or tirzepatide in the past year, and almost half of those users changed how they took the drug on their own — most often by skipping doses — because of cost or supply problems, according to a federal survey published Nov. 12 by the Centers for Disease Control and Prevention.
The report, published in the agency's Morbidity and Mortality Weekly Report, is the first nationally representative CDC data to measure not just how many adults are using the once-a-week injections but how they are actually taking them once a prescription leaves the pharmacy counter. It found that about one in five users had taken a compounded version of the drug — a copy mixed by a pharmacy rather than manufactured by Novo Nordisk or Eli Lilly and never reviewed by the Food and Drug Administration for safety or effectiveness.
What the survey found
Researchers in the CDC's Division of Nutrition, Physical Activity, and Obesity surveyed a nationally representative sample of adults in July and August 2025 about their use of glucagon-like peptide-1, or GLP-1, medications, a class that includes semaglutide (sold as Ozempic and Wegovy) and tirzepatide (Mounjaro and Zepbound). An estimated 9.8% of adults — roughly one in 10 — reported taking a GLP-1 drug in the previous 12 months, with a 95% confidence interval of 9.0% to 10.7%.
Use was higher among women (11.9%) than men (7.6%), and climbed with both age and body weight: 4.8% of adults 18 to 39 had used one of the drugs, compared with 13.7% of those 40 to 64 and 11.1% of those 65 and older. By body mass index, use ranged from 4.7% among adults at a healthy weight to 24.1% among those with class 3 obesity. Use was far more common among people with related chronic conditions — 47.4% of adults with diabetes had taken a GLP-1 drug, compared with 5.7% of those without diabetes, and use was also elevated among people with sleep apnea or cardiovascular disease. A separate CDC data brief based on 2024 survey data had already found that more than one in four adults with diagnosed diabetes used an injectable GLP-1 drug, a figure consistent with the new report's emphasis on chronic-disease patients.
Among those who had used a GLP-1 medication, 22.6% said they had taken a compounded version and another 8.8% said they did not know whether their medication was compounded. Compounded use was more common among women (27.3%) than men (14.8%) and among people with private insurance (25.9%) than those with public coverage (12.5%).
Skipped doses, delayed refills
The more striking finding concerned what people did after they left the pharmacy. About 44% of GLP-1 users told CDC interviewers they had modified their medication use from how it was prescribed. Skipping doses altogether was the most common change, reported by 28% of users; others said they took less medication than prescribed or delayed filling a prescription.
Younger adults were far more likely to adjust their regimen on their own: 54% of users ages 18 to 39 reported modifying use, compared with 30% of those 65 and older, and 37% of younger users said they had delayed filling a prescription versus 6% of older users. Users of compounded medications were also substantially more likely to have modified their use — 62%, compared with 36% among those using only FDA-approved brand-name products.
The reasons were overwhelmingly financial and logistical rather than medical. Among adults who modified their use, 38% cited cost and 36% cited availability or supply problems; cost was named by 58% of users 18 to 39 but only 20% of those 65 and older, a gap the authors linked to differences in insurance coverage. Separately, about 12% of all GLP-1 users said they had cut back or stopped the medication because of side effects.
A compounding market regulators say should have closed
The CDC survey's finding on compounded use lands against a backdrop of unfinished federal enforcement. The FDA allowed pharmacies to compound copies of semaglutide and tirzepatide during the drugs' nationwide shortages, but it determined in a February 2025 memorandum that the semaglutide shortage had been resolved, a decision that was meant to force most compounding pharmacies to stop selling copies within months.
Nearly two years later, compounded versions remain widely available. A University of Colorado Anschutz Medical Campus study published in July in JAMA Health Forum sent researchers posing as patients to 75 storefront weight-loss clinics and medical spas in Oklahoma and West Virginia; 92% still offered compounded semaglutide and 86.7% offered compounded tirzepatide, months after the FDA said supply had normalized. Some of the pharmacies supplying those products lacked licenses required for sterile compounding or had faced prior disciplinary action, the study found.
"Our research shows that the market and supply chain for compounded GLP-1s is highly diffuse. There are so many different types of providers and individual compounding pharmacies involved," said Michael J. DiStefano, the study's lead author and an assistant professor at the University of Colorado Anschutz Medical Campus.
Separate FDA enforcement data cited in trade press this year describe more than 1,150 adverse events, upwards of 100 hospitalizations and at least 10 deaths linked to compounded GLP-1 products since the shortages began, and the agency has sent warning letters to roughly 30 telehealth companies over how they market the copies. A Gallup poll released this year found current GLP-1 use for weight loss has climbed to about 11% of U.S. adults in 2026, up from 3% in 2024, with 19% of current users on a compounded formulation — figures broadly consistent with the CDC's survey.
Who is affected, and what comes next
The CDC authors frame the modified-use findings as a warning sign for both patients and prescribers. GLP-1 drugs are typically dosed on an escalating schedule, and clinicians rely on patients following that schedule to manage side effects and maintain the metabolic and cardiovascular benefits the drugs are approved to provide. Skipped doses, delayed refills and self-adjusted doses can blunt those benefits or, in some cases, reintroduce gastrointestinal side effects when treatment resumes after a gap.
The burden falls disproportionately on younger adults, who were both the most likely to modify their use and the most likely to cite cost as the reason. Brand-name semaglutide and tirzepatide carry list prices close to $1,000 a month before rebates or discounts, and working-age adults often have less generous drug coverage than people on Medicare or Medicaid.
The CDC report does not recommend policy changes, but its authors note that dispensing of GLP-1 drugs has continued to rise since their expanded approval for chronic weight management, and that compounded versions carry risks precisely because they are not reviewed by the FDA for safety, effectiveness or quality. The agency said it plans to continue monitoring use patterns through its National Health Interview Survey, and FDA officials have said enforcement against noncompliant compounders and telehealth marketers will continue. For now, the survey leaves open how many of the roughly 25 million American adults estimated to be using these drugs are taking them as prescribed — and how many are quietly rationing a treatment many say they cannot otherwise afford.
Thanksgiving Travel Set to Dip Slightly as Gas and Airfare Prices Hit Records

FDA recalls Brad's kale and veggie chips after thallium found in tested samples
New York dairy recalls all raw cheddar cheese over Listeria risk, second recall in a month
